Daniele de Paula Faria1, Erik F J de Vries1, Jurgen W A Sijbesma1, Carlos A Buchpiguel2, Rudi A J O Dierckx1, Sjef C V M Copray3. 1. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, The Netherlands. 2. Center of Nuclear Medicine, University of São Paulo, University of São Paulo Medical School, Brazil. 3. Department of Neuroscience, University of Groningen, University Medical Center Groningen, The Netherlands j.c.v.m.copray@umcg.nl.
Abstract
BACKGROUND: Injection of lysolecithin in the central nervous system results in demyelination accompanied by local activation of microglia and recruitment of monocytes. Positron-emission tomography (PET) imaging, using specific tracers, may be an adequate technique to monitor these events in vivo and therefore may become a tool for monitoring disease progression in multiple sclerosis (MS) patients. OBJECTIVES: The objective of this paper is to evaluate the potential of PET imaging in monitoring local lesions, using [(11)C]MeDAS, [(11)C]PK11195 and [(18)F]FDG as PET tracers for myelin density, microglia activation and glucose metabolism, respectively. METHODS: Sprague-Dawley rats were stereotactically injected with either 1% lysolecithin or saline in the corpus callosum and striatum of the right brain hemisphere. PET imaging was performed three days, one week and four weeks after injection. Animals were terminated after PET imaging and the brains were explanted for (immuno)histochemical analysis. RESULTS: PET imaging was able to detect local demyelination induced by lysolecithin in the corpus callosum and striatum with [(11)C]MeDAS and concomitant microglia activation and monocyte recruitment with [(11)C]PK11195. [(18)F]FDG imaging demonstrated that glucose metabolism was maintained in the demyelinated lesions. CONCLUSION: PET imaging with multiple tracers allows simultaneous in vivo monitoring of myelin density, neuroinflammation and brain metabolism in small MS-like lesions, indicating its potential to monitor disease progression in MS patients.
BACKGROUND: Injection of lysolecithin in the central nervous system results in demyelination accompanied by local activation of microglia and recruitment of monocytes. Positron-emission tomography (PET) imaging, using specific tracers, may be an adequate technique to monitor these events in vivo and therefore may become a tool for monitoring disease progression in multiple sclerosis (MS) patients. OBJECTIVES: The objective of this paper is to evaluate the potential of PET imaging in monitoring local lesions, using [(11)C]MeDAS, [(11)C]PK11195 and [(18)F]FDG as PET tracers for myelin density, microglia activation and glucose metabolism, respectively. METHODS:Sprague-Dawley rats were stereotactically injected with either 1% lysolecithin or saline in the corpus callosum and striatum of the right brain hemisphere. PET imaging was performed three days, one week and four weeks after injection. Animals were terminated after PET imaging and the brains were explanted for (immuno)histochemical analysis. RESULTS: PET imaging was able to detect local demyelination induced by lysolecithin in the corpus callosum and striatum with [(11)C]MeDAS and concomitant microglia activation and monocyte recruitment with [(11)C]PK11195. [(18)F]FDG imaging demonstrated that glucose metabolism was maintained in the demyelinated lesions. CONCLUSION: PET imaging with multiple tracers allows simultaneous in vivo monitoring of myelin density, neuroinflammation and brain metabolism in small MS-like lesions, indicating its potential to monitor disease progression in MSpatients.
Authors: Dave E Marzan; Valérie Brügger-Verdon; Brian L West; Shane Liddelow; Jayshree Samanta; James L Salzer Journal: Glia Date: 2021-02-23 Impact factor: 8.073
Authors: David Vállez Garcia; Cindy Casteels; Adam J Schwarz; Rudi A J O Dierckx; Michel Koole; Janine Doorduin Journal: PLoS One Date: 2015-03-30 Impact factor: 3.240
Authors: David Vállez García; Janine Doorduin; Daniele de Paula Faria; Rudi A J O Dierckx; Erik F J de Vries Journal: J Neuroimmune Pharmacol Date: 2017-03-30 Impact factor: 4.147
Authors: Pedro Brugarolas; Jorge E Sánchez-Rodríguez; Hsiu-Ming Tsai; Falguni Basuli; Shih-Hsun Cheng; Xiang Zhang; Andrew V Caprariello; Jerome J Lacroix; Richard Freifelder; Dhanabalan Murali; Onofre DeJesus; Robert H Miller; Rolf E Swenson; Chin-Tu Chen; Peter Herscovitch; Daniel S Reich; Francisco Bezanilla; Brian Popko Journal: Sci Rep Date: 2018-01-12 Impact factor: 4.379
Authors: Andrea Parente; Aren van Waarde; Alexandre Shoji; Daniele de Paula Faria; Bram Maas; Rolf Zijlma; Rudi A J O Dierckx; Johannes A Langendijk; Erik F J de Vries; Janine Doorduin Journal: Mol Imaging Biol Date: 2018-06 Impact factor: 3.488
Authors: Amany El-Shahawy Abdel-Maged; Amany M Gad; Laila Ahmed Rashed; Samar S Azab; Eman A Mohamed; Azza S Awad Journal: Mol Neurobiol Date: 2020-06-08 Impact factor: 5.682